Impacts of an Advanced Practice Physiotherapy Model of Care for Adults With a Peripheral Musculoskeletal Disorders Referred to an Orthropaedic Outpatient Clinic

Musculoskeletal Disorders Clinical Trial

Official title:

Impacts of an Advanced Practice Physiotherapy Model of Care for Adults With a Peripheral Musculoskeletal Disorders Referred to an Orthropaedic Outpatient Clinic: a Prospective Observational Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05714332
• Other study ID #: v3
• Status: Recruiting
• Start date: November 14, 2022
• Est. completion date: February 2024

Study information

• Verified date: August 2023
• Source: Ciusss de L'Est de l'Île de Montréal
• Contact: Simon Lafrance, MSc PT
• Phone: 1+ 438-863-3995
• Email: simon.lafrance.1[@]umontreal.ca
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this prospective observational study is to evaluate advanced practice physiotherapy and orthopedic surgeon care and clinical outcomes for new patients with a peripheral musculoskeletal disorders consulting at the orthopedic outpatient clinic of the Hôpital Jean-Talon. The main questions it aims to answer are: 1. To describe the models of care at the Hôpital Jean-Talon orthopedic outpatient clinic; 2. To assess change in pain, disability, quality of life and pain catastrophizing at 6, 12 and 26 weeks after the initial evaluation; 3. To assess interprofessional collaboration between the advanced practice physiotherapists and orthopedic surgeons; 4. To assess patient satisfaction with care; 5. To assess waiting time before an initial consultation. Researchers will compare patients cared in the advanced practice physiotherapy and orthopedic surgeon group and the orthopedic surgeon only group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 152
• Est. completion date: February 2024
• Est. primary completion date: January 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults with peripheral musculoskeletal disorders
• New consultation at the Hôpital Jean-Talon orthopedic outpatient clinic
• Legally able to consent
• Understand and speak French or English
• Beneficiaries of the provincial universal health insurance coverage (RAMQ)

Exclusion Criteria:

• Patients directly referred from the emergency department (not considered as patients referred to the outpatient clinic).

Related Conditions & MeSH terms

• Musculoskeletal Diseases
• Musculoskeletal Disorders

Intervention

Other:
• Advanced practice physiotherapy and orthopedic surgeon management
Management of their musculoskeletal condition by an advanced practice physiotherapist and an orthopedic surgeon.
• Orthopedic surgeon management
Management of their musculoskeletal condition by an orthopedic surgeon.

Locations

Country	Name	City	State
Canada	Centre de recherche de l'Hôpital Maisonneuve-Rosemont	Montréal	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
Ciusss de L'Est de l'Île de Montréal	CIUSSS du Nord-de-l'Île-de-Montréal

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brief pain inventory severity	Pain questionnaire (0-10; higher score=worse)	6 weeks (change from baseline)
Primary	Brief pain inventory severity	Pain questionnaire (0-10; higher score=worse)	12 weeks (change from baseline)
Primary	Brief pain inventory severity	Pain questionnaire (0-10; higher score=worse)	26 weeks (change from baseline)
Primary	Brief pain inventory inventory	Pain interference (disability) questionnaire (0-10; higher score=worse)	6 weeks (change from baseline)
Primary	Brief pain inventory inventory	Pain interference (disability) questionnaire (0-10; higher score=worse)	12 weeks (change from baseline)
Primary	Brief pain inventory inventory	Pain interference (disability) questionnaire (0-10; higher score=worse)	26 weeks (change from baseline)
Secondary	Shortened Disability of the Arm, Shoulder and Hand (QuickDASH)	Disability questionnaire for upper extremity disorders (0-100; higher=worse)	6 weeks (change from baseline)
Secondary	Shortened Disability of the Arm, Shoulder and Hand (QuickDASH)	Disability questionnaire for upper extremity disorders (0-100; higher=worse)	12 weeks (change from baseline)
Secondary	Shortened Disability of the Arm, Shoulder and Hand (QuickDASH)	Disability questionnaire for upper extremity disorders (0-100; higher=worse)	26 weeks (change from baseline)
Secondary	Hip disability and Osteoarthritis Outcomes Score (HOOS)	Disability questionnaire for hip disorders (0-100; higher=better)	6 weeks (change from baseline)
Secondary	Hip disability and Osteoarthritis Outcomes Score (HOOS)	Disability questionnaire for hip disorders (0-100; higher=better)	12 weeks (change from baseline)
Secondary	Hip disability and Osteoarthritis Outcomes Score (HOOS)	Disability questionnaire for hip disorders (0-100; higher=better)	26 weeks (change from baseline)
Secondary	Knee injury and Osteoarthritis Outcomes Score (KOOS)	Disability questionnaire for knee disorders (0-100; higher=better)	6 weeks (change from baseline)
Secondary	Knee injury and Osteoarthritis Outcomes Score (KOOS)	Disability questionnaire for knee disorders (0-100; higher=better)	12 weeks (change from baseline)
Secondary	Knee injury and Osteoarthritis Outcomes Score (KOOS)	Disability questionnaire for knee disorders (0-100; higher=better)	26 weeks (change from baseline)
Secondary	Foot and Ankle Ability Measure (FAAM)	Disability questionnaire for ankle/foot disorders (0-100; higher=better)	6 weeks (change from baseline)
Secondary	Foot and Ankle Ability Measure (FAAM)	Disability questionnaire for ankle/foot disorders (0-100; higher=better)	12 weeks (change from baseline)
Secondary	Foot and Ankle Ability Measure (FAAM)	Disability questionnaire for ankle/foot disorders (0-100; higher=better)	26 weeks (change from baseline)
Secondary	EQ-5D-5L	Health-related quality of life questionnaire (to be converted in QALYs 0-1; higher=better)	6 weeks (change from baseline)
Secondary	EQ-5D-5L	Health-related quality of life questionnaire (to be converted in QALYs 0-1; higher=better)	12 weeks (change from baseline)
Secondary	EQ-5D-5L	Health-related quality of life questionnaire (to be converted in QALYs 0-1; higher=better)	26 weeks (change from baseline)
Secondary	EQ-5D-VAS	Health-related quality of life questionnaire (0-100; higher=better)	6 weeks (change from baseline)
Secondary	EQ-5D-VAS	Health-related quality of life questionnaire (0-100; higher=better)	12 weeks (change from baseline)
Secondary	EQ-5D-VAS	Health-related quality of life questionnaire (0-100; higher=better)	26 weeks (change from baseline)
Secondary	Pain Catastrophizing Scale (PCS)	Health-related quality of life questionnaire (0-50; higher=worse)	6 weeks (change from baseline)
Secondary	Pain Catastrophizing Scale (PCS)	Health-related quality of life questionnaire (0-50; higher=worse)	12 weeks (change from baseline)
Secondary	Pain Catastrophizing Scale (PCS)	Health-related quality of life questionnaire (0-50; higher=worse)	26 weeks (change from baseline)
Secondary	Patient perceptions of team effectiveness (Patient-PTE)	Perceptions of team effectiveness questionnaire (24-144; higher=better)	0 week (post initial consultation)
Secondary	modified validated version of the 9-item visit-specific satisfaction questionnaire (VSQ-9)	Patient satisfaction questionnaire (0-100; higher=better)	0 week (post initial consultation)
Secondary	Modified MedRisk	Patient satisfaction questionnaire (0-100; higher=better)	12 weeks
Secondary	Modified MedRisk	Patient satisfaction questionnaire (0-100; higher=better)	26 weeks
Secondary	Provider perceptions of team effectiveness (Prodiver-PTE)	Perceptions of team effectiveness questionnaire (26-156; higher=better)	Through study completion (once)
Secondary	Waiting time	Waiting time (time in days and minutes)	Pre-intervention
Secondary	Adverse events	Rate of adverse events	12 weeks
Secondary	Adverse events	Rate of adverse events	26 weeks
Secondary	Treatment and compliance	Treatment received and % of treatment compliance	6 weeks
Secondary	Treatment and compliance	Treatment received and % of treatment compliance	12 weeks
Secondary	Treatment and compliance	Treatment received and % of treatment compliance	26 weeks